0001104659-24-128019.txt : 20241212 0001104659-24-128019.hdr.sgml : 20241212 20241212161513 ACCESSION NUMBER: 0001104659-24-128019 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20241212 DATE AS OF CHANGE: 20241212 EFFECTIVENESS DATE: 20241212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Transcode Therapeutics, Inc. CENTRAL INDEX KEY: 0001829635 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 811065054 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-531946 FILM NUMBER: 241544984 BUSINESS ADDRESS: STREET 1: 6 LIBERTY SQUARE STREET 2: #2382 CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 857-301-6857 MAIL ADDRESS: STREET 1: 6 LIBERTY SQUARE STREET 2: #2382 CITY: BOSTON STATE: MA ZIP: 02109 D 1 primary_doc.xml X0708 D LIVE 0001829635 Transcode Therapeutics, Inc. 6 LIBERTY SQUARE, #2382 BOSTON MA MASSACHUSETTS 02109 857-837-3099 DELAWARE None None Corporation true Thomas A. Fitzgerald 6 Liberty Square, #2382 Boston MA MASSACHUSETTS 02109 Executive Officer Director Erik Manting 6 Liberty Square, #2382 Boston MA MASSACHUSETTS 02109 Director Magda Marquet 6 Liberty Square, #2382 Boston MA MASSACHUSETTS 02109 Director Philippe Calais 6 Liberty Square, #2382 Boston MA MASSACHUSETTS 02109 Director Biotechnology No Revenues 06b false 2024-12-02 false true true true false 0 The Benchmark Company LLC 000022982 None None 150 E 58th Street 17th Floor New York NY NEW YORK 10155 All States false A.G.P./Alliance Global Partners 000008361 None None 88 Post Road West 2nd Floor Westport CT CONNECTICUT 06880 All States false 8000000 8000000 0 false 6 320000 0 The Benchmark Company LLC acted as the exclusive placement agent for the Private Placement and the Company paid them a cash fee. Also, the Company engaged A.G.P./Alliance Global Partners as financial advisor and paid them an expense fee and a cash fee. 0 false Transcode Therapeutics, Inc. /s/ Thomas A. Fitzgerald Thomas A. Fitzgerald Interim Chief Executive Officer; Chief Financial Officer 2024-12-12